Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Aronora (Details)

v3.20.2
Royalty Purchase Agreements - Aronora (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Agreements            
Long-term royalty receivables     $ 34,375 $ 34,375   $ 34,375 [1]
Payments of contingent consideration     0 0    
Changes in estimated fair value of contingent consideration       0    
Impairment of long-term royalty receivable       0   $ 0
Payments to acquire milestones and royalties         $ 6,300  
Proceeds from issuance of long-term debt         $ 3,000  
Aronora            
Agreements            
Contingent consideration liability     $ 0 0    
Royalty Purchase Agreement | Aronora            
Agreements            
Number of drug candidates | item 5          
Non-royalties to be received (as a percent) 10.00%          
Future non-royalty payments to be received (as a percent) 5.00%          
Multiplier for cumulative amount of consideration paid | item 2          
Upfront payment $ 6,000          
Threshold amount of cumulative royalties on net sales per product 250,000          
Long-term royalty receivables 9,000          
Contingent consideration liability 3,000          
Payments of contingent consideration   $ 3,000        
Impairment of long-term royalty receivable       $ 0    
Aggregate milestones payments per product 85,000          
Royalty Purchase Agreement | Aronora | Silicon Valley Bank Loans            
Agreements            
Upfront payment $ 3,000          
Royalty Purchase Agreement | Aronora | Bayer Products            
Agreements            
Number of drug candidates | item 3          
Number of drug candidates subject to exclusive license option | item 1          
Royalties on net sales of products (as a percent) 100.00%          
Non-royalties to be received (as a percent) 10.00%          
Contingent future cash payment for each product $ 1,000          
Potential future cash payments $ 3,000          
Royalty Purchase Agreement | Aronora | Non-Bayer Products            
Agreements            
Number of drug candidates | item 2          
Non-royalties to be received (as a percent) 10.00%          
[1] The consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.